share_log

Vivos Therapeutics | EFFECT: Others

SEC ·  Apr 29 18:14
Summary by Futu AI
Vivos Therapeutics, Inc., a company listed in the United States, has achieved a significant milestone with the Securities and Exchange Commission (SEC) declaring its Form S-1 effective as of April 26, 2024, at 4:30 P.M. The Form S-1 is a registration statement that companies must file with the SEC before they can proceed with the sale of securities to the public. The effectiveness of this form indicates that Vivos Therapeutics has met all the regulatory requirements set forth by the SEC, paving the way for a potential public offering or other securities-related activities.
Vivos Therapeutics, Inc., a company listed in the United States, has achieved a significant milestone with the Securities and Exchange Commission (SEC) declaring its Form S-1 effective as of April 26, 2024, at 4:30 P.M. The Form S-1 is a registration statement that companies must file with the SEC before they can proceed with the sale of securities to the public. The effectiveness of this form indicates that Vivos Therapeutics has met all the regulatory requirements set forth by the SEC, paving the way for a potential public offering or other securities-related activities.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.